 Pauline Merrill
Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveitis | 5 | 2020 | 8 | 1.500 |
Why?
| | Uveitis, Posterior | 3 | 2020 | 3 | 1.260 |
Why?
| | Sirolimus | 3 | 2020 | 22 | 1.180 |
Why?
| | Posterior Eye Segment | 2 | 2020 | 2 | 1.020 |
Why?
| | Macular Edema | 1 | 2019 | 4 | 0.790 |
Why?
| | Immunologic Factors | 1 | 2019 | 50 | 0.760 |
Why?
| | Rickettsia Infections | 1 | 2016 | 1 | 0.630 |
Why?
| | Retinitis | 1 | 2016 | 3 | 0.630 |
Why?
| | Eye Infections, Bacterial | 1 | 2016 | 5 | 0.630 |
Why?
| | Visual Acuity | 5 | 2020 | 47 | 0.510 |
Why?
| | Double-Blind Method | 4 | 2020 | 550 | 0.450 |
Why?
| | Panuveitis | 2 | 2020 | 2 | 0.410 |
Why?
| | Uveitis, Intermediate | 2 | 2020 | 2 | 0.410 |
Why?
| | Immunosuppressive Agents | 3 | 2020 | 167 | 0.390 |
Why?
| | Intravitreal Injections | 4 | 2020 | 8 | 0.340 |
Why?
| | Female | 11 | 2020 | 18107 | 0.300 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2020 | 527 | 0.280 |
Why?
| | Middle Aged | 11 | 2020 | 11256 | 0.270 |
Why?
| | Adrenal Cortex Hormones | 2 | 2016 | 99 | 0.260 |
Why?
| | Humans | 16 | 2020 | 30741 | 0.260 |
Why?
| | Vision Disorders | 2 | 2019 | 26 | 0.260 |
Why?
| | Tomography, Optical Coherence | 2 | 2020 | 22 | 0.250 |
Why?
| | Choroid Diseases | 1 | 2002 | 4 | 0.240 |
Why?
| | Time Factors | 4 | 2020 | 1911 | 0.240 |
Why?
| | Retinal Diseases | 1 | 2002 | 10 | 0.240 |
Why?
| | Treatment Failure | 2 | 2020 | 188 | 0.240 |
Why?
| | Electronic Health Records | 2 | 2019 | 77 | 0.220 |
Why?
| | Aged | 8 | 2020 | 10156 | 0.220 |
Why?
| | Intraocular Pressure | 1 | 2020 | 8 | 0.210 |
Why?
| | Databases, Factual | 2 | 2019 | 372 | 0.200 |
Why?
| | Uveitis, Anterior | 1 | 2019 | 5 | 0.200 |
Why?
| | Spondylarthropathies | 1 | 2019 | 9 | 0.200 |
Why?
| | Follow-Up Studies | 3 | 2020 | 2046 | 0.200 |
Why?
| | Anti-Inflammatory Agents | 2 | 2020 | 109 | 0.200 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 230 | 0.200 |
Why?
| | Proportional Hazards Models | 1 | 2020 | 385 | 0.190 |
Why?
| | Treatment Outcome | 5 | 2020 | 3850 | 0.190 |
Why?
| | Adult | 8 | 2020 | 9760 | 0.190 |
Why?
| | International Classification of Diseases | 1 | 2018 | 25 | 0.190 |
Why?
| | Male | 9 | 2020 | 17552 | 0.190 |
Why?
| | Academic Medical Centers | 1 | 2019 | 162 | 0.180 |
Why?
| | Retinal Necrosis Syndrome, Acute | 2 | 2008 | 2 | 0.170 |
Why?
| | Retina | 1 | 2016 | 17 | 0.170 |
Why?
| | Rickettsia | 1 | 2016 | 1 | 0.160 |
Why?
| | Chorioretinitis | 1 | 2016 | 3 | 0.160 |
Why?
| | HLA-A Antigens | 1 | 2016 | 13 | 0.160 |
Why?
| | Africa | 1 | 2016 | 12 | 0.160 |
Why?
| | Travel | 1 | 2016 | 15 | 0.160 |
Why?
| | Retinal Neoplasms | 1 | 2013 | 1 | 0.140 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 49 | 0.130 |
Why?
| | Lymphoma | 1 | 2013 | 58 | 0.130 |
Why?
| | Ocular Hypotension | 1 | 2012 | 1 | 0.120 |
Why?
| | Retrospective Studies | 5 | 2020 | 3456 | 0.120 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 321 | 0.110 |
Why?
| | Eye Infections, Viral | 1 | 2008 | 2 | 0.090 |
Why?
| | Drug Resistance, Viral | 1 | 2008 | 43 | 0.090 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2008 | 49 | 0.090 |
Why?
| | Young Adult | 3 | 2020 | 2249 | 0.070 |
Why?
| | Vasculitis, Central Nervous System | 1 | 2004 | 3 | 0.070 |
Why?
| | Magnetic Resonance Angiography | 1 | 2004 | 51 | 0.070 |
Why?
| | Prevalence | 2 | 2019 | 546 | 0.070 |
Why?
| | Risk Factors | 2 | 2019 | 2611 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2020 | 5172 | 0.060 |
Why?
| | Exudates and Transudates | 1 | 2002 | 1 | 0.060 |
Why?
| | Remission, Spontaneous | 1 | 2002 | 11 | 0.060 |
Why?
| | Injections, Subcutaneous | 1 | 2020 | 45 | 0.060 |
Why?
| | Women's Health | 1 | 2002 | 220 | 0.050 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 13 | 0.050 |
Why?
| | Computer Systems | 1 | 2018 | 6 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2018 | 39 | 0.050 |
Why?
| | Adolescent | 2 | 2016 | 2627 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 631 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 594 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 386 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2016 | 247 | 0.040 |
Why?
| | Chicago | 1 | 2019 | 945 | 0.040 |
Why?
| | Prognosis | 1 | 2019 | 1045 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2018 | 875 | 0.040 |
Why?
| | Acute Disease | 1 | 2016 | 272 | 0.040 |
Why?
| | Animals | 2 | 2018 | 5221 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 239 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 469 | 0.030 |
Why?
| | Chronic Disease | 1 | 2016 | 542 | 0.030 |
Why?
| | Acyclovir | 1 | 2008 | 6 | 0.020 |
Why?
| | Ganciclovir | 1 | 2008 | 26 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 2008 | 56 | 0.020 |
Why?
| | Prednisone | 1 | 2008 | 76 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 266 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2012 | 1233 | 0.020 |
Why?
|
|
Merrill's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|